Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017

Published:2020-01-01 Issue:1 Volume:6 Page:154
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Seiger Kira¹²³,Mostaghimi Arash³,Silk Ann W.⁴,Schmults Chrysalyne D.³,Ruiz Emily Stamell³

Affiliation:

1. Harvard Medical School, Boston, Massachusetts

2. Harvard Business School, Boston, Massachusetts

3. Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts

4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2754742/jamaoncology_seiger_2019_ld_190022.pdf

Reference6 articles.

1. Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014.;Dusetzina;JAMA Oncol,2016

2. Five years of cancer drug approvals: innovation, efficacy, and costs.;Mailankody;JAMA Oncol,2015

3. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019.;Dusetzina;JAMA,2019

4. Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure.;Bennette;Health Aff (Millwood),2016

5. Research and development spending to bring a single cancer drug to market and revenues after approval.;Prasad;JAMA Intern Med,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Machine Learning Methods for Precision Dosing in Anticancer Drug Therapy: A Scoping Review;Clinical Pharmacokinetics;2024-08-17

2. Economic Cost and Sustainability of Oral Therapies in Precision Oncology;JCO Oncology Practice;2022-08

3. When competition is not enough: leveraging US policies to curb oral anticancer drug costs;The Lancet Oncology;2022-07

4. Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer;Expert Review of Pharmacoeconomics & Outcomes Research;2022-04-29

5. Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review;Journal of Oncology Pharmacy Practice;2022-01-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3